ST Wanbang's New Drug WP107 Multi-Dose Escalation Clinical Study Approved by US FDA

Regulation
โดย 证券时报·Read original
Summary · why it matters

ST Wanbang announced that its wholly-owned subsidiary Wanbangde Pharmaceutical Group has independently developed a new drug WP107, an oral solution of huperzine A, for the treatment of generalized myasthenia gravis. It has recently received approval from the US Food and Drug Administration to conduct a multi-dose escalation clinical trial in healthy study participants.

Impact on stocks 1

Others▲ · 1 stocks
© 2026 MarketDXNews